Comments
Loading...

NextCure Analyst Ratings

NXTCNASDAQ
Logo brought to you by Benzinga Data
$0.4380
0.036.31%
At close: -
$0.4174
-0.02-4.70%
After Hours: May 15, 6:23 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$15.00
Lowest Price Target1
$3.00
Consensus Price Target1
$7.00

NextCure Analyst Ratings and Price Targets | NASDAQ:NXTC | Benzinga

NextCure Inc has a consensus price target of $7 based on the ratings of 5 analysts. The high is $15 issued by Truist Securities on August 23, 2022. The low is $3 issued by HC Wainwright & Co. on March 17, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on March 17, 2025, March 7, 2025, and November 11, 2024, respectively. With an average price target of $3.33 between HC Wainwright & Co., there's an implied 698.59% upside for NextCure Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
2
Mar
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.1
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Needham
Piper Sandler
Truist Securities

1calculated from analyst ratings

Analyst Ratings for NextCure

Buy NowGet Alert
03/17/2025Buy Now618.74%HC Wainwright & Co.
Emily Bodnar37%
$3 → $3ReiteratesBuy → BuyGet Alert
03/07/2025Buy Now618.74%HC Wainwright & Co.
Emily Bodnar37%
$4 → $3ReiteratesBuy → BuyGet Alert
11/11/2024Buy Now858.31%HC Wainwright & Co.
Emily Bodnar37%
$8 → $4MaintainsBuyGet Alert
08/02/2024Buy Now858.31%Needham
Gil Blum49%
$4 → $4ReiteratesBuy → BuyGet Alert
06/03/2024Buy Now1816.63%HC Wainwright & Co.
Emily Bodnar37%
$8 → $8ReiteratesBuy → BuyGet Alert
05/31/2024Buy Now1816.63%HC Wainwright & Co.
Emily Bodnar37%
$8 → $8ReiteratesBuy → BuyGet Alert
05/03/2024Buy Now1816.63%HC Wainwright & Co.
Emily Bodnar37%
$8 → $8ReiteratesBuy → BuyGet Alert
05/03/2024Buy Now858.31%Needham
Gil Blum49%
$4 → $4ReiteratesBuy → BuyGet Alert
03/22/2024Buy Now1816.63%HC Wainwright & Co.
Emily Bodnar37%
$5 → $8MaintainsBuyGet Alert
03/20/2024Buy Now858.31%Needham
Gil Blum49%
$4 → $4MaintainsBuyGet Alert
12/14/2023Buy Now858.31%Needham
Gil Blum49%
$6 → $4MaintainsBuyGet Alert
08/08/2023Buy Now1577.05%HC Wainwright & Co.
Emily Bodnar37%
→ $7Initiates → BuyGet Alert
08/04/2023Buy Now1337.47%Needham
Gil Blum49%
→ $6ReiteratesBuy → BuyGet Alert
05/05/2023Buy Now1337.47%Needham
Gil Blum49%
→ $6Reiterates → BuyGet Alert
03/03/2023Buy Now1337.47%Needham
Gil Blum49%
→ $6Reiterates → BuyGet Alert
11/04/2022Buy Now—Ladenburg Thalmann
Aydin Huseynov33%
—DowngradeBuy → NeutralGet Alert
11/04/2022Buy Now1337.47%Needham
Gil Blum49%
$12 → $6MaintainsBuyGet Alert
11/04/2022Buy Now1337.47%Piper Sandler
Edward Tenthoff50%
$13 → $6MaintainsOverweightGet Alert
08/23/2022Buy Now3493.68%Truist Securities
Asthika Goonewardene41%
$19 → $15MaintainsBuyGet Alert
05/23/2022Buy Now3014.52%Piper Sandler
Edward Tenthoff50%
$21 → $13MaintainsOverweightGet Alert

FAQ

Q

What is the target price for NextCure (NXTC) stock?

A

The latest price target for NextCure (NASDAQ:NXTC) was reported by HC Wainwright & Co. on March 17, 2025. The analyst firm set a price target for $3.00 expecting NXTC to rise to within 12 months (a possible 618.74% upside). 6 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for NextCure (NXTC)?

A

The latest analyst rating for NextCure (NASDAQ:NXTC) was provided by HC Wainwright & Co., and NextCure reiterated their buy rating.

Q

When was the last upgrade for NextCure (NXTC)?

A

There is no last upgrade for NextCure

Q

When was the last downgrade for NextCure (NXTC)?

A

The last downgrade for NextCure Inc happened on November 4, 2022 when Ladenburg Thalmann changed their price target from N/A to N/A for NextCure Inc.

Q

When is the next analyst rating going to be posted or updated for NextCure (NXTC)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NextCure, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NextCure was filed on March 17, 2025 so you should expect the next rating to be made available sometime around March 17, 2026.

Q

Is the Analyst Rating NextCure (NXTC) correct?

A

While ratings are subjective and will change, the latest NextCure (NXTC) rating was a reiterated with a price target of $3.00 to $3.00. The current price NextCure (NXTC) is trading at is $0.42, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch